肺癌外泌体应用中面临挑战的最新进展
Recent advances to address challenges in extracellular vesicle-based applications for lung cancer
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:14.6
分区:医学1区 Top / 药学1区
发表日期:2024 Sep
作者:
Gaigai Huang, Wenshu Zheng, Yu Zhou, Meihua Wan, Tony Hu
DOI:
10.1016/j.apsb.2024.06.010
摘要
肺癌高发，是全球癌症相关死亡的主要原因，因缺乏早期诊断的明确肿瘤标志物及个性化治疗手段，仍是重大挑战。近年来，外泌体（EVs）作为细胞间自然信使载体，因其能穿越生物屏障并携带多种生物载体（包括细胞质蛋白、细胞表面蛋白、microRNA、lncRNA、circRNA、DNA和脂质），受到广泛关注。EVs被认为是无创液体活检的重要资源，也可作为药物递送平台及抗癌疫苗，用于肺癌的精准治疗。鉴于肿瘤相关EV在肺癌发生中的作用及其诊断和治疗潜力，本文从转化医学角度探讨其作用机制，并展望先进工程技术如何克服当前挑战，加快EVs从实验室研究到临床应用的转化。
Abstract
Lung cancer, highly prevalent and the leading cause of cancer-related death globally, persists as a significant challenge due to the lack of definitive tumor markers for early diagnosis and personalized therapeutic interventions. Recently, extracellular vesicles (EVs), functioning as natural carriers for intercellular communication, have received increasing attention due to their ability to traverse biological barriers and deliver diverse biological cargoes, including cytosolic proteins, cell surface proteins, microRNA, lncRNA, circRNA, DNA, and lipids. EVs are increasingly recognized as a valuable resource for non-invasive liquid biopsy, as well as drug delivery platforms, and anticancer vaccines for precision medicine in lung cancer. Herein, given the diagnostic and therapeutic potential of tumor-associated EVs for lung cancer, we discuss this topic from a translational standpoint. We delve into the specific roles that EVs play in lung cancer carcinogenesis and offer a particular perspective on how advanced engineering technologies can overcome the current challenges and expedite and/or enhance the translation of EVs from laboratory research to clinical settings.